{"links":{"html":"https://www.erudio.com/reports/linker-al2-nct06292780","json":"https://www.erudio.com/reports/linker-al2-nct06292780.json","markdown":"https://www.erudio.com/reports/linker-al2-nct06292780.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"linker-al2-06292780"}},"request":"https://www.erudio.com/contact?report=linker-al2-06292780"},"offer":{"cited_commentary_sources":25,"verified_hcp_statements":149,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":13,"optional":true,"price_per_verified_person_usd":15,"price_usd":195,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"linker-al2-nct06292780"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=linker-al2-06292780","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/linker-al2-nct06292780","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T17:15:28.468920Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":7,"title":"Primary endpoint: Incidence of dose-limiting toxicity (DLTs)"},{"claim_count":14,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":10,"title":"Primary endpoint: Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)"},{"claim_count":26,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":13,"title":"Secondary endpoints"},{"claim_count":35,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":10,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":16,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":22,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":9,"title":"Design and conduct"},{"claim_count":10,"coverage":"discussed","id":"A1","source_count":7,"title":"Second-line positioning after Dara-CyBorD"},{"claim_count":13,"coverage":"discussed","id":"A2","source_count":8,"title":"Comparative impressions and mechanistic rationale"},{"claim_count":16,"coverage":"discussed","id":"A3","source_count":3,"title":"Defining progression and deciding when to retreat"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":4,"title":"Alternative trials and sequencing with CAR-T"},{"claim_count":21,"coverage":"discussed","id":"A5","source_count":9,"title":"Referral, local delivery and patient navigation"},{"claim_count":15,"coverage":"discussed","id":"A6","source_count":9,"title":"Evidence-generation priorities and development constraints"}],"counts":{"cited_sources":25,"claims_by_expression_type":{"comparison":12,"experience":3,"interpretation":32,"opinion":25,"primary_context":7,"question":4,"restatement":51,"uncertainty":5,"unspecified":10},"claims_by_kind":{"source_observation":149},"clinician_statements":50,"evidence_units":93,"findings":9,"organisational_accounts":5,"people_cited":15,"people_identity_verified":13,"people_total":15,"screened_sources":44,"verified_claims":149},"findings_index":[{"id":"F1","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":2,"questions":0,"restated":3,"views":6},"has_counterview":false,"limitations":4,"links":{"context":0,"support":12},"ma_question":true,"named_voices":7,"passages":9,"sources":7,"sources_by_kind":{"commentary":2,"media":5}},"title":"A consequential second-line positioning proposal comes from one clinician, not an established consensus"},{"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":6,"views":3},"has_counterview":false,"limitations":5,"links":{"context":0,"support":12},"ma_question":true,"named_voices":6,"passages":8,"sources":6,"sources_by_kind":{"commentary":2,"media":4}},"title":"Favorable tolerability assessments must travel with the serious infection and severe adverse-event observations"},{"id":"F3","structure":{"claims":37,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":12,"views":21},"has_counterview":true,"limitations":6,"links":{"context":2,"support":41},"ma_question":true,"named_voices":12,"passages":24,"sources":12,"sources_by_kind":{"commentary":7,"media":5}},"title":"Rapid light-chain suppression drives enthusiasm, while meaningful organ recovery remains an explicitly open question for some authors"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":5,"experience":0,"questions":0,"restated":3,"views":2},"has_counterview":false,"limitations":3,"links":{"context":1,"support":10},"ma_question":true,"named_voices":9,"passages":9,"sources":8,"sources_by_kind":{"commentary":2,"media":6}},"title":"The strongest comparative language is experiential or mechanistic, not evidence of comparative efficacy"},{"id":"F5","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":9,"views":5},"has_counterview":false,"limitations":3,"links":{"context":0,"support":19},"ma_question":true,"named_voices":1,"passages":9,"sources":3,"sources_by_kind":{"media":3}},"title":"Retreatment timing involves both avoiding delay and avoiding unnecessary treatment toxicity"},{"id":"F6","structure":{"claims":23,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":13,"views":6},"has_counterview":false,"limitations":3,"links":{"context":2,"support":29},"ma_question":true,"named_voices":2,"passages":19,"sources":5,"sources_by_kind":{"media":5}},"title":"Eligibility and work-up shape who can act on the encouraging findings"},{"id":"F7","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":2,"views":4},"has_counterview":false,"limitations":5,"links":{"context":0,"support":9},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"Bispecific-versus-CAR-T choice includes urgency, repeated administration and preservation of later trial options"},{"id":"F8","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":2,"questions":2,"restated":8,"views":8},"has_counterview":false,"limitations":4,"links":{"context":0,"support":27},"ma_question":true,"named_voices":7,"passages":22,"sources":9,"sources_by_kind":{"commentary":3,"media":6}},"title":"Could off-the-shelf delivery extend access beyond specialist centers?"},{"id":"F9","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":10,"views":6},"has_counterview":false,"limitations":5,"links":{"context":1,"support":18},"ma_question":true,"named_voices":6,"passages":16,"sources":10,"sources_by_kind":{"commentary":1,"media":9}},"title":"What must Phase II establish, and what constrains AL-specific development?"}],"medical_affairs_question":"What additional organ-recovery, durability, safety and sequencing evidence would justify routine second-line positioning rather than trial-based or individually accessed use?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Second-line positioning: an individual proposal with immediate practical consequences"},{"id":"section-2","level":2,"title":"Safety: manageability does not mean absence of substantial harm"},{"id":"section-3","level":2,"title":"Response speed: the clinical rationale is stronger than a response-rate headline"},{"id":"section-4","level":2,"title":"Comparative impressions: preserve the enthusiasm and its exceptions"},{"id":"section-5","level":2,"title":"Retreatment timing: earlier action and caution can both be clinically motivated"},{"id":"section-6","level":2,"title":"Selection and work-up: the highest-need patients may fall outside the early experience"},{"id":"section-7","level":2,"title":"Sequencing: immediate availability can affect what remains possible later"},{"id":"section-8","level":2,"title":"Access and delivery: a drug can be off the shelf while care remains specialist-dependent"},{"id":"section-9","level":2,"title":"Further development: what is needed to establish effectiveness and pursue licensing?"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":1}],"id":"T1","label":"Primary endpoint: Incidence of dose-limiting toxicity (DLTs)"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":14},{"id":"F4","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T2","label":"Primary endpoint: Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":25},{"id":"F7","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":23},{"id":"F8","shared_claims":3},{"id":"F9","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":10},{"id":"F3","shared_claims":7},{"id":"F4","shared_claims":3},{"id":"F7","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":2},{"id":"F8","shared_claims":4},{"id":"F9","shared_claims":12}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T17:15:28.468920Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T17:25:16Z","record_hash":"b0d93a3cfd4cf6c0068a6a509381b2266fcb33060a064c51814171f24276b544","release_hash":"b9eba02fc797ce0668f18505cf5edeffc8e48ee2680dff9b9abe083b58844b8d","report_id":"erudio-nct06292780","run_id":"18d6584a-d0c9-4145-b407-af8124eb0324","schema_version":"5.0","slug":"linker-al2-06292780","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"LINKER-AL2 studies linvoseltamab safety and hematologic complete response in relapsed/refractory systemic light-chain amyloidosis; second-line BCMA bispecific positioning is one clinician’s proposal. The report cites 10 physicians, including five medical oncologists and one hematology-oncology physician, and includes speakers described in the sources reviewed for this edition as presenting the trial; questions also concern meaningful organ recovery and serious infections. What organ-recovery, durability, safety and sequencing evidence would justify routine second-line use beyond trials or individual access? The sources place LINKER-AL2’s initial Phase I dose-escalation results at ASCO 2026.","meta_description":"44 sources screened · 149 verified statements (50 from clinicians verified by NPI or staff page) from 25 sources · 9 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-939726e2b70fc04b85ab"],"id":"F3","paraphrase":"A hematology-oncology physician on a podcast addressed how the timing of hematologic responses relates to organ-response timing in LINKER-AL2.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"podcast","source_date":"2026-09-03","title":"Rapid light-chain suppression drives enthusiasm, while meaningful organ recovery remains an explicitly open question for some authors"},{"cited_claim_ids":["claim-650bd3251b70377e4cf2"],"id":"F9","paraphrase":"The report distinguishes a physician’s question on X about future development from results in the LINKER-AL2 study population.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-05-29","title":"What must Phase II establish, and what constrains AL-specific development?"}]},"publication":{"approved_at":"2026-11-01T17:25:16Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":44},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on fatal treatment-emergent adverse events during treatment for relapsed or refractory systemic light chain amyloidosis.","Not yet captured in this edition: a view on eligibility, treatment burden and recruitment access for investigational alternatives in relapsed or refractory light-chain amyloidosis.","Not yet captured in this edition: a view on access to investigational cellular therapy as an alternative for relapsed or refractory AL amyloidosis.","Not yet captured in this edition: a view on access constraints and care-team assessment for alternative investigational treatment in relapsed or refractory AL amyloidosis.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","127 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, repeated summaries and accounts of the same dataset should not be counted as independent clinical confirmation.","Some potentially relevant social posts and a webinar passage were not fully evaluated, including safety commentary. The report therefore may not capture every consequential reported harm or qualification.","Information about alternatives is incomplete: NEXICART-2's study phase and recruiting locations are not fully described, and eligibility, treatment schedules and practical access for ABBV-383 and remantamig are incompletely covered. This limits comparisons of trial suitability and access.","Discussion that does not name the study or uses different wording may be missing.","No exact-trial results publication, protocol document or exact linvoseltamab label was available for this edition. Source-reported response figures, follow-up, administration descriptions and safety details could not be fully reconciled against those documents.","The early treatment appraisals concern a small cohort and exclude the most advanced cardiac involvement; they cannot establish safety or benefit for all patients with relapsed/refractory AL amyloidosis.","Some podcast and webinar passages cannot be assigned to a named speaker and remain unnamed. A participant list does not show who said those words.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Enrollment locations and availability are historical descriptions from the relevant webinars, not assurances of current access. Planned locations should not be assumed to have been enrolling. Publication dates do not establish session dates or changes in opinion."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":1,"youtube":8},"by_evidence_role":{"commentary":25},"count":25,"evidence_window":{"end":"2026-09-03","start":"2024-09-13"},"retrieval_snapshot":"2026-11-01T15:38:15.249769Z","timeline":[{"count":1,"week":"2024-W37"},{"count":1,"week":"2025-W16"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2026-W17"},{"count":8,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W25"},{"count":3,"week":"2026-W26"},{"count":2,"week":"2026-W28"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W36"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06292780:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06292780:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cgpwq6jbgzg5zb3sshw24l57-3mmyss5tg322p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-yk5mvwzdjpy45i4ph7at4xmx-3mov2f7t7222g","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:909715","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1983733046005400024:a0b1b53b-fd42-44b3-ac16-02f6e09e1d9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057568627109273831:89f93758-e6a6-4d0a-8ab0-d0bc42013765","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058143498478731386:f4d01d21-35d2-493d-b189-fb18518b9068","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058600545066086605:82ea7ca0-e18e-4dcc-a7ef-cd64cc3238d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058953968965845322:342c12d7-206d-4ba7-bd7c-2c5363947c6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059354231044554878:83cf67dd-2620-411d-8245-cb85d20b068b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060073620919992558:1b50b4e3-eb17-4e38-9765-360f52229c77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060213586392187182:7d42d085-7c01-41ca-a8f8-810ab4bf7c6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060298272233923021:794b46ae-5078-41d8-9489-b3699c66e4dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060456092128223624:aeae2f2a-6c1a-4fcb-ac52-5f9f4cf07da0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060456123287621643:baea49cc-4bb1-485a-b4b4-b0a862837850","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060456410861752666:5632e228-b9ad-4fb7-8938-fc3ed082e047","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060457117249581191:66b998dc-4c88-4dc6-9b45-07da94005de9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060476082072289747:630c70fb-4d74-4719-9035-fb1bff5ff833","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060502626249408612:30650a8d-2e9f-412a-83c7-b29a445f3749","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060659836107493828:669e73fe-a7d3-40ba-b8a9-3177cf439e06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060729673189838951:a19add44-a7a6-40e6-be9d-0e22cd042ad8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061158041735606538:c4bb936c-a9de-4f03-adff-5132b85dd67e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062580326765932980:bd1afd81-600e-4174-9b5d-366704d4003a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2063003075913171235:814eb6ea-89bb-4175-8484-2b62af833a70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064785755176853504:2968fb7a-d069-49fe-bde8-5df1f0d8ce67","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065468287543038356:5e4e7d40-a10b-4d1c-bf7c-ff282e352c3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065473678096158784:867e92d7-eb94-4486-bd74-80cc6fb5350b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065709574166913201:f495564b-4780-4806-98db-a067d9719a0c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066173825604280375:bbd24562-b0d9-48c1-867b-671239d98187","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069058347827917079:43041e26-9618-4513-9287-bcca51ec20b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069084309353369902:841ddd22-2096-47d0-b66c-845f00651ef3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2070145107207012844:bd226736-5a2c-4809-96c6-135421bb7b2a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074116153501479344:71019813-e7b1-4495-85dc-f05d655d9b8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088264400691921128:055ecf4a-a712-4b0f-8759-b5e95f3ae9de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095785929353101682:6fa00baf-c6e7-4485-8936-90bd62b311a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113899393711571447:10622681-54b9-4563-8512-f14bf37fa901","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2066173825604280375","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:CRSS-1D2K-Q","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DCSGd_M32-c","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KQ-AHHv9o5Q","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:KgITCnxY4GY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZrepfThei1k","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:gsq_5S79UzA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ivlN2nGxsdY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ub8K3Pvw5-0","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":32,"x_video":1,"youtube":8},"by_evidence_role":{"commentary":44},"count":44,"evidence_window":{"end":"2026-10-24","start":"2024-09-13"},"retrieval_snapshot":"2026-11-01T15:38:15.249769Z","timeline":[{"count":1,"week":"2024-W37"},{"count":1,"week":"2025-W16"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2026-W17"},{"count":3,"week":"2026-W21"},{"count":15,"week":"2026-W22"},{"count":3,"week":"2026-W23"},{"count":6,"week":"2026-W24"},{"count":1,"week":"2026-W25"},{"count":4,"week":"2026-W26"},{"count":2,"week":"2026-W28"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W33"},{"count":2,"week":"2026-W36"},{"count":1,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: linvoseltamab","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Relapsed/Refractory Systemic Light Chain Amyloidosis","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"LINKER-AL2","aliases":["LINKER-AL2","A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)","A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis"],"brief_title":"A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Relapsed/Refractory Systemic Light Chain Amyloidosis"],"display_condition":"relapsed or refractory systemic light chain amyloidosis","display_interventions":[["linvoseltamab"]],"enrollment":{"count":220,"type":"ESTIMATED"},"interventions":[{"name":"Linvoseltamab","synonyms":["REGN5458","Lynozyfic™"],"type":"DRUG"}],"nct_id":"NCT06292780","official_title":"A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-08-20","type":"ESTIMATED"},"primary_endpoints":[{"description":"Phase 1","measure":"Incidence of dose-limiting toxicity (DLTs)","timeFrame":"Up to 28 Days"},{"description":"Phase 2","measure":"Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)","timeFrame":"Up to 3 years"}],"registered_date":{"date":"2024-03-05","type":"ACTUAL"},"registry_last_updated":"2026-08-18","registry_url":"https://clinicaltrials.gov/study/NCT06292780","short_name":"LINKER-AL2","short_name_basis":"registry_acronym","sponsor":"Regeneron Pharmaceuticals","start_date":{"date":"2024-08-07","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1, phase2","study_ids":[{"id":"R5458-ONC-2274","type":"sponsor_study_id"},{"id":"2023-507809-34-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}